United States Pharmaceutical Supply Chain Review Act
Latest Action
Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The United States Pharmaceutical Supply Chain Review Act (S. 5206) was a Senate bill introduced in the 118th Congress aimed at reviewing the pharmaceutical supply chain within the United States. The bill was referred to the Committee on Banking, Housing, and Urban Affairs after being read twice. However, no official summary or full text is available, and the bill ultimately failed or expired without further legislative action. The bill falls under the health policy area and appears intended to address issues related to the pharmaceutical supply chain, though specific provisions and objectives are not detailed in the available data.
S. 5206 sought to initiate a review of the U.S. pharmaceutical supply chain but did not advance beyond committee referral and expired without enactment.
- The bill was introduced in the Senate during the 118th Congress and referred to the Committee on Banking, Housing, and Urban Affairs.
- No official summary or full text of the bill is publicly available, limiting detailed analysis of its provisions.
- The bill is categorized under the health policy area and relates to the pharmaceutical supply chain.
['Federal agencies involved in pharmaceutical regulation and supply chain oversight', 'Pharmaceutical manufacturers and distributors', 'Healthcare providers and patients potentially impacted by supply chain stability']
['Lack of publicly available bill text and summary limits understanding of implementation requirements and costs', 'Unclear authority and oversight mechanisms due to absence of detailed provisions', 'Potential overlap or jurisdictional issues given referral to a committee not typically focused on health policy']
The bill was introduced in the Senate and referred to the Committee on Banking, Housing, and Urban Affairs but did not progress further and expired. The referral to this committee suggests a focus on financial or economic aspects of the pharmaceutical supply chain. The bill's failure to advance indicates limited legislative momentum or prioritization during the 118th Congress.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['A review of the pharmaceutical supply chain could lead to future legislative or regulatory proposals aimed at improving supply chain resilience or addressing vulnerabilities.', 'Engagement of financial oversight committees may introduce economic or market-based considerations into pharmaceutical supply chain policy discussions.']
The absence of an official summary and full bill text limits transparency and public understanding of the bill's scope and provisions. Additionally, the referral to a committee outside the typical health jurisdiction may affect the depth of policy expertise applied during review. These factors highlight challenges in legislative transparency and committee jurisdiction alignment for bills addressing complex health-related supply chain issues.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.